Am I the only one reading it negatively?
PXS so far has failed everything they approached: NASH and Diabetic indications with BI, LOXL-2 dead in water after bragging deals for over 3 years.
Don't credit Bronchitol to the current management, as it was developed before 2015 by the previous team and brought to FDA/US by Chiesi.
Now without any real progress in past 3 years, their started with fresh attempt 5505 and even a scar/burn trail...any reasonable investors will naturally ask the question: why should we trust them?
Ann: Investor Presentation, page-4
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
